The “Global Generic Drugs Market 2016-2020” report predicts that the expiry of patents for branded drugs, worth $150 billion, will allow generic companies to prosper by 2020.
Sequenom has filed a patent infringement lawsuit against Sonic Healthcare, Australian Clinical Labs and Ariosa Diagnostics at the Australian Federal Court.
For something to be innovative it must “add value” and companies must ensure they understand the term in order to succeed, the 2016 BIO International Convention has heard.
Biotech was the only technology area out of 12 studied that has shown a global decline in its year-on-year innovation, declining by 2%, according to the “2016 State of Innovation Report: Disruptive, Game-Changing Innovation” by Thomson Reuters.
Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.
Australia’s patent system is “poorly targeted” and protection for pharmaceutical inventions is “excessive”, according to a government advisory committee.
Advocate group Médecins Sans Frontières delivered a suitcase full of syringes to the London headquarters of pharmaceutical company GSK in protest at the price of a pneumonia vaccine.
The US has been ranked as the country that contributes most to global biopharmaceutical innovation through the use of its policies.
Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.
Pharmaceutical company Teva is set to re-brand itself as part of its plan to build “a new breed of healthcare company”.